Pioneering diagnostics

Clinical diagnostics

More than 60 % of medical decisions draw upon the results of in vitro diagnostic tests. These tests contribute to the effectiveness of patient care and greater control over healthcare spending.

In vitro diagnostics are essential in the medical decision-making process and account for only 2% to 3% of healthcare spending. Diagnostic tests offer both medical and economic advantages. They enable doctors to prescribe the most appropriate treatment for a patient's illness and reduce the risk and cost of trial-and-error treatment and over-prescription.

How do they work?

Diagnostic tests analyze biological samples (blood, saliva, urine, etc.) taken from patients. They detect and quantify the presence of pathogens (bacteria, viruses, yeast) or substances secreted by the human body (measurement of the level of a hormone or marker specific to a disease, etc.).

Analysis laboratories use reagents and instruments developed by the in vitro diagnostics (IVD) industry. These tests enable:

  • certain populations to be screened systematically,
  • a diagnosis to be made or confirmed in patients presenting symptoms,
  • appropriate treatment decisions to be made,
  • the chosen treatments to be monitored.

bioMérieux solutions

bioMérieux's diagnostic solutions contribute to the decision-making process for many diseases. We focus in particular on:

The future of diagnostics

Great progress has been made in medicine and the life sciences: the development of new technologies has led to significant changes in the role of diagnostics. Faster time-to-results and the detection of disease at an earlier stage enable patients to receive the appropriate treatment more quickly. A closer link is being forged between diagnostic tests and treatment. Most new therapies are supported by an accompanying in vitro diagnostic test.